{"commentary":{"count":5,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"TRITON","nct_id":"NCT06008093","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=triton-nct06008093. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"TRITON","arms":[{"description":"Participants will receive durvalumab plus tremelimumab every 3 weeks (q3w) for four 21-day cycles in combination with chemotherapy followed by maintenance treatment period (durvalumab plus pemetrexed maintenance) every 4 weeks (q4w) until clinical progression or confirmed RECIST 1.1- defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of participant consent, or EOS, whichever comes first. During the maintenance treatment period, participants will receive additional doses of tremelimumab at Cycle 6 (Week 16) and Cycle 28 (Week 104 - at Investigator's discretion) along with durvalumab and pemetrexed.","label":"Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab regimen q3w for four 21-day cycles in combination with chemotherapy as induction treatment followed by maintenance treatment (pembrolizumab plus pemetrexed maintenance) q3w for up to 24 months, until clinical progression or confirmed RECIST 1.1- defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of participant consent, or EOS, whichever comes first.","label":"Arm B: Pembrolizumab + Platinum-based Chemotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-02-28","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":103,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","type":"DRUG"},{"name":"Tremelimumab","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"}],"last_update":"2026-07-02","lead_sponsor":"AstraZeneca","official_title":"A Phase IIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-10-23","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) in randomized participants","timeFrame":"From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)"},{"measure":"PFS at 6 months","timeFrame":"From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)"},{"measure":"PFS at 12 months","timeFrame":"From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)"}],"references":[{"citation":"Skoulidis F, Borghaei H, Garon EB, Leal TA, Kaufman J, Liu SV, Nadler E, Patel SP, Peters S, Ricciuti B, Gautam A, Emeribe U, Luciani-Silverman L, Heymach JV. Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study. Ther Adv Med Oncol. 2025 Nov 6;17:17588359251386611. doi: 10.1177/17588359251386611. eCollection 2025.","pmid":"41209621","type":"DERIVED"}],"start_date":{"date":"2024-04-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","url":"https://clinicaltrials.gov/study/NCT06008093"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/triton-nct06008093"}